Claudio Laudani/X
Aug 8, 2025, 15:28
Claudio Laudani: New Insights on P2Y12 Monotherapy in Antiplatelet Therapy
Claudio Laudani, Cardiovascular Disease Fellow UNICT, Post-Doc Research Scholar UFHealth JAX, shared a post on X:
”The landscape of antiplatelets has changed in the last decade, shifting from the initial focus on long-term DAPT to P2Y12 inhibitor monotherapy. In this review, we summarize the pharmacology and clinical evidence on antiplatelet montherapy.”
Read the full article here.
Title: Antiplatelet Monotherapies for Long-Term Secondary Prevention Following Percutaneous Coronary Intervention
Authors: Claudio Laudani, Daniele Giacoppo, Antonio Greco, Luis Ortega-Paz, Georges El Khoury, Davide Capodanno, Dominick J. Angiolillo
Stay updated with Hemostasis Today.
-
Sep 30, 2026, 22:28Recent Mechanical Risk Factors and Young-Onset Cryptogenic Ischemic Stroke – American Heart Association International
-
Sep 30, 2026, 22:22Expert Consensus on Inferior Vena Cava Thrombosis – Thrombosis and Haemostasis Journal
-
Sep 30, 2026, 22:21Markus Abeln: How Platelets, Coagulation, Glycosylation, and Complement Regulate Placental Blood Flow
-
Sep 30, 2026, 22:19Fatma Al Arbawi: Studying Blood Clot Mechanics to Understand Aspirin Resistance and Thrombosis
-
Sep 30, 2026, 22:17Sudhir Kumar: Stroke is a Medical Emergency – and Every Minute Matters
-
Sep 30, 2026, 22:15Luisa Medeiros Visentini: Our Research on Cognitive Impairment After CVT Cited in the International Journal of Stroke
-
Sep 30, 2026, 21:50Jagat Narula: Connecting Cardiovascular Health and Sickle Cell Disease on World Heart Day 2026
-
Sep 30, 2026, 21:38John Kastelein: Exploring the Biology of Cardiovascular Disease at BioCentury Grand Rounds Europe
-
Sep 30, 2026, 21:36Mark Murphy: Irish Heart Foundation Meets With Senator Teresa Costello on World Heart Day